Comparison of Pgp- and MRP-mediated multidrug resistance in leukemia cell lines. 2002

Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
Department of Hematology, the First Affiliated Hospital, West China University of Medical Science, Chengdu, Sichuan, PR China.

Drug resistance is a major cause of the failure of anticancer chemotherapy. Multidrug resistance is often caused by overexpression of the P-glycoprotein (Pgp) or the multidrug resistance-related protein (MRP). In the present study, we compared daunorubicin (DNR) accumulation, subcellular distribution, and the effect of modulators on drug accumulation and subcellular distribution in the Pgp-expressing K562 cell line and the MRP-expressing HL60 cell line using reverse-transcriptase polymerase chain reaction, MTT (3-[4, 5-dimethylthiazol-z-yl]-2,5-diphenyltetrazolium bromide) drug cytotoxicity assay, fluorocytometry, and confocal laser scanning microscopy. The 2 resistant cell lines exhibit similar levels of resistance to DNR and decreased drug accumulation. Altered drug subcellular distribution in the resistant cell lines compared to that in the sensitive cell lines was shown and, moreover, differences in drug distributions between the 2 resistant cell lines were found. DNR fluorescence in the resistant HL60 cell line was distributed into punctate regions in the cytoplasm; the nucleus and other cytoplasm were almost negative. In contrast, the resistant K562 cells showed a bright fluorescent signal located in the peripheral cytoplasm and perinuclear region; the nucleus and other cytoplasmic regions showed no signal. Use of the modulator verapamil increased drug accumulation and restored the altered subcellular distribution of the drug in the 2 resistant cell lines. The Golgi apparatus inhibitor brefeldin A had similar action in the resistant HL60 line but had little effect in the resistant K562 line. Therefore, our study suggested that there were differences between the 2 resistant cell lines in the compartments sequestering DNR.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020014 K562 Cells An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS. Cells, K562
D020168 ATP Binding Cassette Transporter, Subfamily B, Member 1 A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE). ATP-Dependent Translocase ABCB1,MDR1 Protein,MDR1B Protein,Multidrug Resistance Protein 1,P-Glycoprotein,P-Glycoprotein 1,ABCB1 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 1,ATP-Binding Cassette, Sub-Family B, Member 1,CD243 Antigen,PGY-1 Protein,1, P-Glycoprotein,ABCB1, ATP-Dependent Translocase,ATP Dependent Translocase ABCB1,Antigen, CD243,P Glycoprotein,P Glycoprotein 1,PGY 1 Protein,Protein, MDR1B,Translocase ABCB1, ATP-Dependent
D027425 Multidrug Resistance-Associated Proteins A sequence-related subfamily of ATP-BINDING CASSETTE TRANSPORTERS that actively transport organic substrates. Although considered organic anion transporters, a subset of proteins in this family have also been shown to convey drug resistance to neutral organic drugs. Their cellular function may have clinical significance for CHEMOTHERAPY in that they transport a variety of ANTINEOPLASTIC AGENTS. Overexpression of proteins in this class by NEOPLASMS is considered a possible mechanism in the development of multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although similar in function to P-GLYCOPROTEINS, the proteins in this class share little sequence homology to the ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 family of proteins. Multidrug Resistance-Associated Protein,ATP-Binding Cassette, Sub-Family C Proteins,MOAT Protein,Multispecific Organic Anion Transport Proteins,Multispecific Organic Anion Transporter,ATP Binding Cassette, Sub Family C Proteins,Multidrug Resistance Associated Protein,Multidrug Resistance Associated Proteins,Resistance-Associated Protein, Multidrug

Related Publications

Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
October 1996, Biochemical pharmacology,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
June 2002, The Journal of veterinary medical science,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
October 1996, Cancer letters,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
June 1996, European journal of cancer (Oxford, England : 1990),
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
October 1995, Leukemia,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
January 1997, British journal of cancer,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
May 1997, Nihon rinsho. Japanese journal of clinical medicine,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
March 2000, British journal of haematology,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
August 1996, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yu-Ping Gong, and Ting Liu, and Yong-Qian Jia, and Li Qin, and Cheng-Qi Deng, and Ren-Yang Ou Yang
February 2005, Journal of medicinal chemistry,
Copied contents to your clipboard!